According to Teva Pharmaceuticals Europe, the company has received marketing authorization in the EU for duplicate DPIs Seffalair Spiromax salmeterol xinafoate/ fluticasone propionate and BroPair Spiromax salmeterol xinafoate/ fluticasone propionate for the treatment for asthma in patients aged 12 and older. The company said that the Spiromax device “has been well received by healthcare professionals and patients” since the 2014 European launch of DuoResp Spiromax budesonide/formoterol. Teva also noted that it plans to launch Seffalair Spiromax and BroPair Spiromax first in Portugal, Switzerland, Spain, and the UK.
Teva Respiratory Europe Head Paul Blonk commented, “We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma. We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”
Read the Teva Pharmaceuticals press release.
